Blog

Bipolar disorder has two sides - the highs (mania) and the lows (depression). For most people, the lows are where they spend most of their time, and the lows are usually what does the most damage to work, relationships, and day-to-day life. They're also the harder side to treat. Most bipolar medications are aimed at the highs, and many people try one after another for years without finding something that holds. TMS - a treatment that uses gentle magnetic pulses to the brain - is giving some of these patients a real option. But bipolar depression is trickier than regular depression, so we want to be straight with you about what TMS can and can't do, what the research actually shows, and how treatment works if you decide to try it. Is TMS approved for bipolar depression? Not yet. Right now, TMS is officially approved by the FDA for regular (non-bipolar) depression, for OCD, and for teens aged 15 and up with regular depression. For bipolar depression, doctors use it "off-label" - meaning it's allowed and widely used, but it doesn't yet carry a formal FDA approval for that specific condition. There has been a big step forward, though. In 2020, the FDA gave the NeuroStar TMS device - the one we use at Creative Wellness - something called a Breakthrough Device Designation for bipolar depression. That's the FDA saying, in effect: "This looks promising enough that we want to help it move through the approval pipeline faster." It's not full approval yet. But it's nothing either. Does it actually work? There's growing evidence that TMS can ease symptoms of bipolar depression - enough that the FDA granted NeuroStar (the device we use) Breakthrough Device Designation in 2020 to formally evaluate it for this use. Results vary from person to person. Some people respond well, some don't. We don't promise outcomes. What we can say confidently is that TMS is well-tolerated and safe for people with bipolar depression, without the systemic side effects that come with most bipolar medications.  One important note: there's some evidence that TMS can occasionally trigger a manic episode in a small number of bipolar patients. It's rare, but real - which is why we monitor closely throughout treatment. Before starting, an accurate diagnosis matters. Some patients have been labelled bipolar when the diagnosis isn't entirely clear, and a careful review sometimes identifies regular (unipolar) depression as the better fit, which changes the treatment plan and what insurance will cover.

First responders carry something most people don't: the cumulative weight of traumatic events, repeated over years, absorbed as part of the job. The hypervigilance that keeps you sharp on a shift doesn't switch off when you go home. The images don't fade on schedule. Sleep gets harder. Reactions get bigger. Relationships get harder to hold onto. For many first responders, the symptoms build quietly for years before anyone names them. Some people call it burnout. Some call it stress. Clinically, it often meets the criteria for PTSD, treatment-resistant depression, or both. This post is about one treatment option that's increasingly being used for people in this situation: transcranial magnetic stimulation (TMS). This non-drug treatment works directly on the brain circuits driving these symptoms. Why first responders are at higher risk Working in emergency services is a recognised risk factor for PTSD . It sits alongside combat exposure, childhood trauma, and other situations where the brain gets pushed into survival mode repeatedly and struggles to come back down. Roughly 7 to 9% of people will experience PTSD at some point in their lifetime. For people in emergency services roles, the exposure is repeated and cumulative - it's not one big event but the tenth, the fiftieth, the hundredth. The math changes. One more thing to know: PTSD rarely travels alone. Roughly half of the people with PTSD also have depression. Anxiety, sleep problems, and substance use often come into the picture too. What might look like "just depression" or "just not sleeping well" is often something more layered. What's actually happening When you go through something life-threatening, your brain drops into a survival mode - hypervigilant, on edge, ready to react. Normally, once the danger passes, your brain returns to its usual state. With repeated or severe trauma, that reset doesn't fully happen. Certain pathways get stuck on high alert. The practical result is a brain that keeps sounding the alarm when there's no fire. That's the hypervigilance, the startle response, the inability to fully relax. It's not a character flaw or weakness. It's a biological pattern - and that means it's something that can be changed with the right treatment. What PTSD actually looks like The symptoms tend to fall into four groups: Intrusive thoughts - flashbacks, nightmares, distressing memories that show up without warning Negative mood and thinking - persistent fear, anger, guilt, or shame; feeling detached from people you used to feel close to; loss of interest in things you used to enjoy. Being constantly on edge - easily startled, struggling to sleep, trouble concentrating, irritability or aggression Avoidance - steering clear of anything that brings it back Any of these can make normal life harder - holding down a job, keeping relationships intact, making decisions, and getting proper rest. Left untreated, PTSD also raises the risk of depression, suicidal thoughts, and substance misuse. Will insurance cover it? It depends on the diagnosis and the insurer. For treatment-resistant depression, TMS is FDA-approved and covered by most plans when the paperwork supports it . For PTSD specifically, coverage is less consistent - some insurers approve it, others don't. When both are present, there's often a clear path to coverage through the depression diagnosis, with PTSD adjustments added during the same course. We check your coverage upfront and are straight with you about costs either way. No surprises.

For most patients, the insurance approval process for TMS is a black box. You submit information, wait, and eventually hear yes or no - often without a clear understanding of what happened in between or why the decision went the way it did. That lack of visibility is a problem because what happens behind the scenes matters. A well-prepared prior authorization submission significantly improves the likelihood of approval. A poorly documented one - or one that misses a specific insurer’s criteria - can result in a denial that takes weeks to appeal, delaying treatment the patient genuinely needs. Why TMS Requires Prior Authorization TMS is an FDA-approved treatment, but FDA approval and insurance coverage are entirely separate things. Insurers make their own coverage determinations based on their own clinical policies, which vary by provider and are updated periodically as the evidence base evolves. Most major insurers in Washington now cover TMS for treatment-resistant major depressive disorder, but they require prior authorization - a formal request from the treating clinic that demonstrates the patient meets their specific eligibility criteria before treatment begins. This is standard for any high-cost or specialist treatment, not unique to TMS. The keyword is “before.” Starting treatment without authorization in place is a significant financial risk. If coverage is denied after treatment has begun, the patient may be liable for the full cost. A clinic that allows this to happen is not doing its job. What Insurers Typically Require Each insurer has its own coverage policy, but most share a common set of core requirements. Understanding these in advance helps you arrive at your evaluation with the right history documented. Diagnosis T MS is covered fo r major depressive dis order (MDD) and, with some insurers, OCD . The diagnosis must be formally documented by a qualified clinician. Off-label uses - anxiety, PTSD, and others - are generally not covered, though this varies and is worth checking with your specific insurer. Prior medication trials Most insurers require documented evidence that the patient has tried and failed to respond to a minimum number of antidepressants - typically two to four, from different drug classes, at adequate doses and durations. “Failed to respond” means either no meaningful improvement or side effects that made the medication intolerable. This documentation needs to be specific: drug names, doses, duration, and outcome. Symptom severity Insurers typically require evidence of moderate to severe depression, usually demonstrated through a validated rating scale score. This is part of why the clinical evaluation matters - it generates the baseline data that supports the authorization request. Prior psychotherapy Some insurers also require documented evidence of prior psychotherapy, typically a course of CBT or equivalent. This requirement is not universal, but it appears in enough coverage policies that it is worth checking early. Medical necessity statement The treating clinician must provide a written statement explaining why TMS is medically necessary for this specific patient, given their history and current presentation. Vague or generic statements are a common reason for denials. The documentation needs to tell a clear, specific clinical story.

TMS is often described as a standalone treatment - and it can be. But the research, and clinical experience, point consistently in the same direction: patients who combine TMS with evidence-based therapy tend to do better. Not marginally better. Meaningfully better, with stronger outcomes and longer-lasting results. This article explains why that is, how CBT and ERP specifically complement what TMS does neurologically, and how care coordination works in practice when you’re receiving both treatments - whether from Creative Wellness directly or from an external therapy provider. Why TMS and Therapy Target Different Things TMS works by delivering magnetic pulses to specific areas of the brain involved in mood regulation. For depression, the primary target is the left dorsolateral prefrontal cortex - a region that is typically underactive in people with major depressive disorder. Repeated stimulation over a course of treatment helps restore more normal activity patterns in these neural circuits. What TMS does not do is change how you think. It does not teach coping skills, restructure unhelpful thought patterns, or help you process experiences that may be contributing to your symptoms. That is what therapy does. This is not a limitation of TMS - it is simply a different mechanism. The two approaches address different dimensions of the same condition. TMS creates the neurological conditions for improvement; therapy builds the cognitive and behavioural skills to sustain it. Used together, each makes the other more effective. What Is CBT and Why Does It Pair Well With TMS? Cognitive Behavioural Therapy (CBT) is one of the most extensively researched psychological treatments available. It is based on the principle that thoughts, feelings, and behaviours are interconnected - and that changing unhelpful thought patterns can directly improve mood and reduce symptoms. In practice, CBT helps patients identify automatic negative thoughts (such as catastrophising, black-and-white thinking, or self-blame), examine their accuracy, and replace them with more balanced, realistic perspectives. It also addresses behavioural patterns - particularly avoidance and withdrawal - that tend to maintain and deepen depression. The pairing with TMS is logical. TMS can lift the neurological floor - reducing the severity of depressive symptoms enough for a patient to engage meaningfully in therapy. Many patients find that CBT feels impossible when they are at their lowest; the cognitive effort required is simply too great. TMS can change that. As brain activity normalises, the capacity to engage with and benefit from therapy increases. Conversely, the insights and skills developed in CBT help protect the gains made through TMS. Depression tends to recur, and one of the strongest predictors of relapse is the absence of coping skills when symptoms begin to return . CBT directly addresses this vulnerability.

Finding the right antidepressant is, for many people, a frustrating process of trial and error. You try a medication, wait four to six weeks to assess whether it’s working, adjust the dose, manage side effects, and if it doesn’t work, start again with something else. For patients with treatment-resistant depression, this cycle can stretch across years. Pharmacogenetic testing - genetic testing applied to medication selection - is one of the more meaningful advances in psychiatric care precisely because it addresses this problem directly. At Creative Wellness TMS, we offer genetic testing as part of our integrated approach to treatment planning. This article explains what it is, how it works, and when it’s most useful alongside TMS and medication management. What Is Pharmacogenetic Testing? Pharmacogenetics is the study of how your genes affect your response to drugs. The same medication at the same dose can produce very different outcomes in different people - some respond well, some experience significant side effects , and some metabolize the drug so quickly or slowly that it never reaches a therapeutic level in the body. These differences are largely genetic. Variations in specific genes - particularly those governing liver enzymes responsible for drug metabolism - determine how your body processes psychiatric medications. By analyzing these genes, clinicians can make more informed decisions about which medications are likely to work for you, which are likely to cause problems, and at what dose. At Creative Wellness, the test examines 18 genes relevant to psychiatric medication response. It is completed across two appointments: a sample is collected at the first session, and results are reviewed with your clinician approximately two weeks later. Learn More: Genetic Testing Explained: Why We Offer It & What It Changes What the Results Actually Tell Your Clinician Genetic test results are typically presented in categories that reflect how your body is likely to process specific medications: Poor metabolizers process a drug more slowly than average, meaning standard doses can accumulate to levels that cause side effects. Rapid or ultrarapid metabolizers clear the drug too quickly for it to reach effective concentrations, which can explain why a medication appears not to work even at standard doses. Normal metabolizers fall within the expected range, meaning standard prescribing guidelines apply. This information is applied across the main classes of psychiatric medication - SSRIs, SNRIs, tricyclics, antipsychotics, mood stabilizers, and others. It tells your clinician which drugs from each class are likely to be well-tolerated and effective, which to approach with caution, and which to avoid. It is worth being clear about what the test does not do: it does not predict with certainty that a specific medication will work. Genetics is one factor among several - diagnosis, symptom profile, lifestyle, and other medications all play a role. But it substantially narrows the field and gives prescribing decisions a more solid foundation than symptom history alone.